Title:
OLIGONUCLEIC ACID CONJUGATE
Document Type and Number:
WIPO Patent Application WO/2022/075459
Kind Code:
A1
Abstract:
The purpose of the present invention is to increase the amount of oligonucleic acid transported into the cytoplasm by bringing about an efficient interaction of a cell uptake promoter with a target cell. An oligonucleic acid conjugate according to the present invention comprises a dendritic polymer, a plurality of oligonucleic acids, one or a plurality of cell uptake promoters, and one or a plurality of hydrophilic linkers. Each oligonucleic acid is bonded to the dendritic polymer directly or through a linker, and each cell uptake promoter is bonded to the dendritic polymer through the hydrophilic linker.
More Like This:
| JP6940636 | Protoxin-II mutant and how to use it |
| JP2022533268 | Gene knockout of variant NRF2 for treating cancer |
| WO/2022/224257 | INTRACELLULAR DELIVERY COMPOSITIONS |
Inventors:
UESAKA AKIHIRO (JP)
MAKITA NAOKI (JP)
TAKEDA MASASHI (JP)
MAKITA NAOKI (JP)
TAKEDA MASASHI (JP)
Application Number:
PCT/JP2021/037412
Publication Date:
April 14, 2022
Filing Date:
October 08, 2021
Export Citation:
Assignee:
SUMITOMO DAINIPPON PHARMA CO LTD (JP)
International Classes:
A61K47/64; A61K9/51; A61K31/7105; A61K38/08; A61K38/10; A61K38/12; A61P43/00; C12N15/113
Domestic Patent References:
| WO2013062982A1 | 2013-05-02 | |||
| WO2013062982A1 | 2013-05-02 |
Foreign References:
| JP2011530537A | 2011-12-22 | |||
| JP2018512858A | 2018-05-24 | |||
| JP2007532662A | 2007-11-15 | |||
| JP2009524679A | 2009-07-02 |
Other References:
OHYAMA AYUMU, HIGASHI TAISHI, MOTOYAMA KEIICHI, ARIMA HIDETOSHI: "In Vitro and In Vivo Tumor-Targeting siRNA Delivery Using Folate-PEG-appended Dendrimer (G4)/α-Cyclodextrin Conjugates", BIOCONJUGATE CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 27, no. 3, 16 March 2016 (2016-03-16), US , pages 521 - 532, XP055920058, ISSN: 1043-1802, DOI: 10.1021/acs.bioconjchem.5b00545
CHARLES L. MCCORMICK ET AL., BIOMACROMOLECULES, vol. 11, 2010, pages 505 - 514
ONCOTARGET, vol. 6, no. 26, 2015, pages 22270 - 22281
SCIENTIFIC REPORTS, vol. 6, 2016, pages 1 - 12
MOLECULAR CANCER THERAPEUTICS, vol. 14, no. 10, 2015, pages 2279 - 2291
THERANOSTICS, vol. 5, no. 10, 2015, pages 1083 - 1097
PROC NATL ACAD SCI USA., vol. 105, no. 41, 2008, pages 15908 - 15913
MOL THER NUCLEIC ACIDS, vol. 3, no. 1, 2014, pages 144
CHARLES L. MCCORMICK ET AL., BIOMACROMOLECULES, vol. 11, 2010, pages 505 - 514
ONCOTARGET, vol. 6, no. 26, 2015, pages 22270 - 22281
SCIENTIFIC REPORTS, vol. 6, 2016, pages 1 - 12
MOLECULAR CANCER THERAPEUTICS, vol. 14, no. 10, 2015, pages 2279 - 2291
THERANOSTICS, vol. 5, no. 10, 2015, pages 1083 - 1097
PROC NATL ACAD SCI USA., vol. 105, no. 41, 2008, pages 15908 - 15913
MOL THER NUCLEIC ACIDS, vol. 3, no. 1, 2014, pages 144
Attorney, Agent or Firm:
HASEGAWA Yoshiki et al. (JP)
Download PDF:
Previous Patent: NOVEL USE OF MYCOBACTERIUM TUBERCULOSIS EXTRACT
Next Patent: HOMOGENEOUS β-1,3-GLUCAN/NUCLEIC ACID COMPLEX AND USE THEREOF
Next Patent: HOMOGENEOUS β-1,3-GLUCAN/NUCLEIC ACID COMPLEX AND USE THEREOF